Literature DB >> 15136493

Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention.

Hoong Sern Lim1, Andrew D Blann, Gregory Y H Lip.   

Abstract

BACKGROUND: High levels of the soluble fragment of CD40 ligand (sCD40L) have previously been associated with adverse cardiovascular outcomes. CD40L-CD40 interaction has been linked to the pathogenesis of atherothrombotic complications in cardiovascular disease (CVD). We sought to determine whether a "package of care" of intensified multifactorial cardiovascular risk intervention could reduce indices of platelet activation, inflammation, and coagulation in diabetes and whether patients with overt CVD would derive similar benefit compared with those without. METHODS AND
RESULTS: We measured plasma sCD40L, soluble P-selectin (sP-sel, an index of platelet activation), interleukin-6 (IL-6, a proinflammatory cytokine), and tissue factor (TF, an initiator of coagulation) in 97 patients with diabetes mellitus (41 with and 56 without overt CVD) and 39 comparable healthy control subjects. Thirty-six patients with and 32 without overt CVD then participated in a package of care of cardiovascular risk intervention over a period of 1 year. Plasma levels of sCD40L (P<0.001), sP-sel (P<0.001), IL-6 (P=0.001), and TF (P<0.001) were higher in patients with diabetes than in control subjects, with TF levels highest in patients with overt CVD. Multifactorial intervention was associated with significant reductions in sCD40L in both patient groups (both P<0.001), but reductions in sP-sel and TF were seen only in patients without overt CVD. There was no significant change in IL-6 levels in both patient groups.
CONCLUSIONS: Intensive multifactorial risk management can reduce high levels of sCD40L but can only partially correct abnormal platelet activation, inflammation, and coagulation in diabetes, particularly in patients with overt CVD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15136493     DOI: 10.1161/01.CIR.0000129773.70647.94

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  43 in total

1.  Serum concentrations and clinical significance of soluble CD40 ligand in patients with multiple myeloma.

Authors:  G Tsirakis; C A Pappa; F E Psarakis; M Fragioudaki; C Tsioutis; E Stavroulaki; A Boula; M G Alexandrakis
Journal:  Med Oncol       Date:  2012-03-09       Impact factor: 3.064

Review 2.  CD40/CD40L system and vascular disease.

Authors:  F Santilli; S Basili; P Ferroni; G Davì
Journal:  Intern Emerg Med       Date:  2007-11-28       Impact factor: 3.397

3.  State-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus.

Authors:  Dharam J Kumbhani; Steven P Marso; Carlos A Alvarez; Darren K McGuire
Journal:  Curr Cardiovasc Risk Rep       Date:  2015-01

4.  Is the Mean Platelet Volume a Predictive Marker of a Low Apgar Score and Insulin Resistance in Gestational Diabetes Mellitus? A Retrospective Case-Control Study.

Authors:  Levent Kebapcilar; Ayse Gul Kebapcilar; Tolgay Tuyan Ilhan; Suleyman Hilmi Ipekci; Suleyman Baldane; Aybike Pekin; Mustafa Kulaksizoglu; Cetin Celik
Journal:  J Clin Diagn Res       Date:  2016-10-01

5.  The inflammatory receptor CD40 is expressed on human adipocytes: contribution to crosstalk between lymphocytes and adipocytes.

Authors:  M Poggi; J Jager; O Paulmyer-Lacroix; F Peiretti; T Gremeaux; M Verdier; M Grino; A Stepanian; S Msika; R Burcelin; D de Prost; J F Tanti; M C Alessi
Journal:  Diabetologia       Date:  2009-01-31       Impact factor: 10.122

6.  Factors contributing to increased platelet reactivity in people with diabetes.

Authors:  David J Schneider
Journal:  Diabetes Care       Date:  2009-04       Impact factor: 17.152

7.  Cardioembolic stroke in atrial fibrillation-rationale for preventive closure of the left atrial appendage.

Authors:  Boris Leithäuser; Jai-Wun Park
Journal:  Korean Circ J       Date:  2009-11-30       Impact factor: 3.243

8.  Platelet tissue factor synthesis in type 2 diabetic patients is resistant to inhibition by insulin.

Authors:  Anja J Gerrits; Cornelis A Koekman; Timon W van Haeften; Jan Willem N Akkerman
Journal:  Diabetes       Date:  2010-03-03       Impact factor: 9.461

9.  Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients.

Authors:  E Santini; S Madec; V Corretti; E Ferrannini; A Solini
Journal:  J Endocrinol Invest       Date:  2008-07       Impact factor: 4.256

10.  Native platelet aggregation and response to aspirin in persons with the metabolic syndrome and its components.

Authors:  Dhananjay Vaidya; Lisa R Yanek; Nauder Faraday; Taryn F Moy; Lewis C Becker; Diane M Becker
Journal:  Metab Syndr Relat Disord       Date:  2009-08       Impact factor: 1.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.